Table 2.
Multivariable adjusted linear regression analysis of ln-transformed urinary As concentrations with plasma concentrations of IGF1 and IGFBP3 at 9 years
| Outcome | Exposure | All children β (95% CI); p value |
Boys β (95% CI); p value |
Girls β (95% CI); p value |
|---|---|---|---|---|
| IGF1 (ng/mL) | As in urine at GW 8 (ln-transformed) | |||
| Crude model (n = 535/266/269) | 2.2 (− 0.3, 4.7); 0.089 | − 0.1 (− 3.1, 3.0); 0.962 | 3.1 (− 0.6, 6.8); 0.098 | |
| Adjusted modela (n = 513/255/258) | 1.2 (− 1.0, 3.4); 0.285 | − 0.1 (− 2.9, 2.6); 0.928 | 2.4 (− 1.0, 5.8); 0.169 | |
| Adjusted modelb (n = 513/255/258) | 0.1 (− 2.0, 2.1); 0.946 | − 1.4 (− 3.9, 1.0); 0.256 | 1.5 (− 1.9, 4.8); 0.388 | |
| As in urine at 9 years (ln-transformed) | ||||
| Crude model (n = 548/273/275) | 1.0 (− 2.3, 4.2); 0.559 | − 0.3 (− 4.1, 3.5); 0.868 | 0.7 (− 4.1, 5.5); 0.779 | |
| Adjusted modelc (n = 535/267/268) | 0.4 (− 2.3, 3.0); 0.795 | 0.5 (− 2.8, 3.9); 0.750 | − 0.1 (− 4.3, 4.2); 0.980 | |
| IGFBP3 (ng/mL) | As in urine at GW 8 (ln-transformed) | |||
| Crude model (n = 535/266/269) | 98 (36, 160); 0.002 | 86 (0, 171); 0.050 | 95 (6, 183); 0.036 | |
| Adjusted modeld (n = 524/261/263) | 91 (29, 153); 0.004 | 84 (− 3, 171); 0.057 | 97 (8, 187); 0.034 | |
| Adjusted modele (n = 524/261/263) | 76 (19, 133); 0.009 | 85 (12, 159); 0.024 | 76 (− 10, 162); 0.082 | |
| As in urine at 9 years (ln-transformed) | ||||
| Crude model (n = 548/273/275) | 12.3 (− 66, 91); 0.758 | − 1.6 (− 107, 104); 0.976 | 5.1 (− 109, 119); 0.930 | |
| Adjusted modeld (n = 537/268/269) | 0.9 (− 78, 79); 0.983 | − 1.6 (− 109, 106); 0.976 | 5.6 (− 110, 121); 0.924 | |
| Adjusted modele (n = 537/268/269) | − 1.1 (− 72, 70); 0.975 | − 0.4 (− 90, 91); 0.993 | 1.6 (− 107, 111); 0.976 | |
| IGF1/IGFBP3 | As in urine at GW 8 (ln-transformed) | |||
| Crude model (n = 535/266/269) | − 0.001 (− 0.005, 0.003); 0.585 | − 0.004 (− 0.008, 0.000); 0.078 | 0.001 (− 0.005, 0.006); 0.793 | |
| Adjusted modelf (n = 513/255/258) | − 0.002 (− 0.006, 0.001); 0.250 | − 0.004 (− 0.008, 0.000); 0.065 | 0.000 (− 0.006, 0.006); 0.935 | |
| As in urine at 9 years (ln-transformed) | ||||
| Crude model (n = 548/273/275) | 0.001 (− 0.004, 0.005); 0.729 | − 0.001 (− 0.007, 0.004); 0.650 | 0.002 (− 0.005, 0.009); 0.653 | |
| Adjusted modelg (n = 535/267/268) | 0.001 (− 0.004, 0.005); 0.798 | 0.000 (− 0.005, 0.005); 0.970 | 0.001 (− 0.006, 0.008); 0.789 | |
aAdjusted for child sex (except when stratified for sex), HAZ (9 years), BMI (GW 8), plasma CRP (9 years)
bAdjusted for child sex (except when stratified for sex), HAZ (9 years), BMI (GW 8), plasma CRP (9 years), plasma IGFBP3
cAdjusted for child sex (except when stratified for sex), HAZ (9 years), BMI (9 years), plasma CRP (9 years), SES (9 years)
dAdjusted for child sex (except when stratified for sex), plasma CRP (9 years)
eAdjusted for child sex (except when stratified for sex), plasma CRP (9 years), plasma IGF1
fAdjusted for child sex (except when stratified for sex), HAZ (9 years), plasma CRP (9 years), BMI (GW 8)
gAdjusted for child sex (except when stratified for sex), HAZ (9 years), plasma CRP (9 years), SES (9 years), BMI (9 years)